Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Viking Therapeutics (VKTX – Research Report) and Kinnate Biopharma (KNTE – Research Report).
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes, with a price target of $32.00. The company’s shares closed last Wednesday at $27.83.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of
Alkermes has an analyst consensus of Hold, with a price target consensus of $30.25, representing a 3.9% upside. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $28.00 price target.
Viking Therapeutics (VKTX)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, with a price target of $21.00. The company’s shares closed last Wednesday at $3.18.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $15.50, representing a 369.7% upside. In a report issued on July 19, Maxim Group also assigned a Buy rating to the stock with a $10.00 price target.
Kinnate Biopharma (KNTE)
In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on Kinnate Biopharma and a price target of $33.00. The company’s shares closed last Wednesday at $12.04.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kinnate Biopharma with a $31.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALKS:
- Rolls-Royce hires new chief executive; aims to end fossil fuel reliance
- Analyst Richard Hatch is bullish on these two mining stocks that pay strong dividends
- Analyst Explains Why They Downgraded Their Rating on Coursera (COUR)
- Berenberg Bank Maintains Their Buy Rating on Doximity (DOCS)
- Coursera (COUR) Receives a Buy from Needham